Pfizer & BioNTech’s Covid Vaccine Candidate Reaches 95% Efficacy & Will Seek Approval for Use ...Middle East

New York, NY & Mainz, DE… Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that, after conducting the final efficacy analysis in their ongoing Phase 3 study, their mRNA-based COVID-19 vaccine candidate, BNT162b2, met all of the study’s primary efficacy endpoints. Analysis of the data indicates a vaccine efficacy rate of 95% (p There were 10 severe cases of COVID-19 observed in the trial, with nine of the cases occurring in the placebo group and one in the BNT162b2 vaccinated group. To date, the Data Monitoring Committee for the study has not reported any serious safety concerns related to the vaccine. A review of unblinded reactogenicity data from the final analysis wh

Read More Details
Finally We wish PressBee provided you with enough information of ( Pfizer & BioNTech’s Covid Vaccine Candidate Reaches 95% Efficacy & Will Seek Approval for Use )

Also on site :

• On the record: Hubbard
• ForexLive Asia-Pacific FX news wrap: Oil spike on talk of Israel preparing attack on Iran
• ‘My Life Is Complete’: 'Days of Our Lives' Star Shares Emotional First Look at Full Hernandez Family